Cell injection study for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new cell injection (CNK-UT009) for adults with type 1 diabetes. The goal is to see if it can help manage blood sugar and reduce insulin needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 65 years
- Diagnosed with autoimmune type 1 diabetes
- Must have certain antibodies in the blood (like GAD or insulin antibodies)
- C-peptide level between 0.2 and a certain amount after a special meal drink
- Good organ function (heart, lungs, liver, kidneys) and no severe infections or bleeding problems
- No active cancer, recent blood clots, or other serious health issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called GNTI-122 for adults recently diagnosed with type 1 diabetes who still make some insulin. It aims to see if the treatment can help protect the cells that produce insulin.
This trial tests an investigational drug that may help preserve the body's ability to make insulin in people with type 1 diabetes. It aims to slow the progression of the disease and reduce the need for insulin injections.
This trial tests a new one-time treatment called CARC-101C for people recently diagnosed with type 1 diabetes. It aims to see if this treatment can help preserve the body's ability to make insulin and improve blood sugar control.
This Phase 1 study tests a new immune-system strategy around islet transplantation (or donor bone marrow therapy) to improve control of type 1 diabetes and reduce dangerous low blood sugar. It mainly aims to see if the approach is safe and helpful in people with long-standing, difficult-to-manage diabetes.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
This study tests a new medication, MTX228, to see if it can help people with type 1 diabetes who still make some insulin. It may slow the loss of your own insulin production and improve blood sugar control.
Hear when a new Type 1 Diabetes (T1D) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.